New drug targets hard-to-treat cancer mutation in early trial

NCT ID NCT06818812

Ongoing Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests an experimental drug called INCB186748 in people with advanced or spreading solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety and find the right dose. About 30 adults whose cancer has not responded to standard treatments will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

Florida Cancer Specialists

Sarasota, Florida, 34232, United States
Georgetown University Hospital

Washington D.C., District of Columbia, 20007, United States
Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Jefferson University Hospitals

Philadelphia, Pennsylvania, 19107, United States
Md Anderson Cancer Center

Houston, Texas, 77030, United States
Sarah Cannon Research Institue At Healthone

Denver, Colorado, 80218, United States
Scri Oncology Partners

Nashville, Tennessee, 37203, United States
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins

Baltimore, Maryland, 21287-7049, United States
UCLA Healthcare Hematology-Oncology

Santa Monica, California, 90404, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.